Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
- PMID: 33045992
- PMCID: PMC7552488
- DOI: 10.1186/s12866-020-01995-1
Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
Abstract
Background: Multidrug resistant (MDR) Gram-negative bacterial infections are a serious threat to human health due to the lack of effective treatments. In this study, we selected 50 Gram-negative bacterial strains, including 26 strains of Klebsiella pneumoniae and 24 strains of Escherichia coli, to explore whether resveratrol and polymyxin B have a synergistic killing effect.
Results: MIC values against polymyxin B were ≥ 4 μg/mL for 44 of the strains and were 2 μg/mL for the other 6 strains. MICs against polymyxin B in the isolates tested were significantly reduced by the addition of resveratrol. The degree of decline depended on the bacteria, ranging from 1/2 MIC to 1/512 MIC, and the higher the concentration of resveratrol, the greater the decrease. Checkerboard analysis indicated a synergistic effect between resveratrol and polymyxin B; the optimal drug concentration for different bacteria was different, that of resveratrol ranging from 32 μg/mL to 128 μg/mL. Subsequent time-kill experiments showed that a combination of polymyxin B and resveratrol was more effective in killing bacteria.
Conclusions: Our in vitro studies have shown that resveratrol can increase the sensitivity of MDR bacterial strains to polymyxin B, suggesting a potential new approach to the treatment of MDR infections.
Keywords: Combination therapy; Multidrug resistance (MDR); Polymyxin B; Resveratrol.
Conflict of interest statement
The authors declare they have no competing interests.
Figures
Similar articles
-
Evaluation of EDTA and Dipicolinic Acid in Broth Microdilution with Polymyxin B as a Phenotypic Test to Detect the mcr-1 Gene.Microb Drug Resist. 2020 Apr;26(4):329-333. doi: 10.1089/mdr.2019.0172. Epub 2019 Oct 8. Microb Drug Resist. 2020. PMID: 31592718
-
From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.Microb Drug Resist. 2017 Jul;23(5):640-650. doi: 10.1089/mdr.2016.0196. Epub 2016 Dec 9. Microb Drug Resist. 2017. PMID: 27935770
-
In Vitro and In Vivo Effects of the Polymyxin-Vorinostat Combination Therapy Against Multidrug-Resistant Gram-Negative Pathogens.Microb Drug Resist. 2020 Sep;26(9):1108-1119. doi: 10.1089/mdr.2019.0309. Epub 2020 Apr 28. Microb Drug Resist. 2020. PMID: 32349617
-
Polymyxin Resistance Mechanisms: From Intrinsic Resistance to Mcr Genes.Recent Pat Antiinfect Drug Discov. 2018;13(3):198-206. doi: 10.2174/1574891X14666181126142704. Recent Pat Antiinfect Drug Discov. 2018. PMID: 30474535 Review.
-
[Advances in the diagnosis and treatment strategy of polymyxin resistant Klebsiella pneumoniae].Zhonghua Jie He He Hu Xi Za Zhi. 2023 Aug 12;46(8):813-818. doi: 10.3760/cma.j.cn112147-20230418-00188. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 37536993 Review. Chinese.
Cited by
-
The Antimicrobial Potential of the Hop (Humulus lupulus L.) Extract against Staphylococcus aureus and Oral Streptococci.Pharmaceuticals (Basel). 2024 Jan 27;17(2):162. doi: 10.3390/ph17020162. Pharmaceuticals (Basel). 2024. PMID: 38399377 Free PMC article.
-
Polymyxin B and fusidic acid, a novel potent synergistic combination against Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance.Front Microbiol. 2023 Oct 11;14:1220683. doi: 10.3389/fmicb.2023.1220683. eCollection 2023. Front Microbiol. 2023. PMID: 37886061 Free PMC article.
-
Peptide Antibiotic-Polyphosphate Nanoparticles: A Promising Strategy to Overcome the Enzymatic and Mucus Barrier of the Intestine.Biomacromolecules. 2023 Jun 12;24(6):2587-2595. doi: 10.1021/acs.biomac.3c00083. Epub 2023 May 24. Biomacromolecules. 2023. PMID: 37224061 Free PMC article.
-
Phytochemicals as Invaluable Sources of Potent Antimicrobial Agents to Combat Antibiotic Resistance.Life (Basel). 2023 Apr 4;13(4):948. doi: 10.3390/life13040948. Life (Basel). 2023. PMID: 37109477 Free PMC article. Review.
-
Detection of antibiotic-resistant canine origin Escherichia coli and the synergistic effect of magnolol in reducing the resistance of multidrug-resistant Escherichia coli.Front Vet Sci. 2023 Mar 15;10:1104812. doi: 10.3389/fvets.2023.1104812. eCollection 2023. Front Vet Sci. 2023. PMID: 37008355 Free PMC article.
References
-
- Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of A 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–1694. doi: 10.1093/cid/cit152. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
